Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Changes of organ blood flow and cardiac output after imidazole administration

Autor: C, Hably, Z, Györváry, J, Bartha

Publikováno v: Acta physiologica Hungarica. 82(2)

Effects of imidazole, an inhibitor of thromboxane synthesis (10 mg/kg bw., iv.) on the distribution of cardiac output and intrarenal hemodynamics were investigated in normovolemic (free water and salt uptake before the experiment) narcotized rats. Th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9770d7554b0e012c0a349f5ce5a48fc6
https://pubmed.ncbi.nlm.nih.gov/7887176

Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial

Autor: Jean-Yves Blay, Angelica Fasolo, Palanichamy Ilankumaran, Tae Min Kim, Daniel C Cho, Jeffrey Yachnin, Filip de Vos, Martin J. van den Bent, Eduard Gasal, Albert Lai, Antje Wick, Mario Campone, Damien Pouessel, Myra E. van Linde, Alexander Stein, Jacques De Greve, Warren P. Mason, Jose A. Lopez-Martin, Anas Gazzah, Nikolas von Bubnoff, Vivek Subbiah, Gerald W. Prager, Ralf-Dieter Hofheinz, Patrick Y. Wen, Aislyn Boran, Paul Burgess

Publikováno v: The Lancet Oncology, 23(1), 53-64. Lancet Publishing Group
Wen, P Y, Stein, A, van den Bent, M, de Greve, J, Wick, A, de Vos, F Y F L, von Bubnoff, N, van Linde, M E, Lai, A, Prager, G W, Campone, M, Fasolo, A, Lopez-Martin, J A, Kim, T M, Mason, W P, Hofheinz, R-D, Blay, J-Y, Cho, D C, Gazzah, A, Pouessel, D, Yachnin, J, Boran, A, Burgess, P, Ilankumaran, P, Gasal, E & Subbiah, V 2022, ' Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR) : a multicentre, open-label, single-arm, phase 2, basket trial ', The Lancet Oncology, vol. 23, no. 1, pp. 53-64 . https://doi.org/10.1016/S1470-2045(21)00578-7

Background: Effective treatments are needed to improve outcomes for high-grade glioma and low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated in adult patients with recurrent or progressive BRAFV600E mutation-positi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fad158cf6a3776974f72e32f6f4611e
https://pure.eur.nl/en/publications/6534e7d9-0966-4ffb-83ef-1054a6161e37

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Autor: Cook, Audrey, Beesley, Sharon, O'Sullivan, Joe M, Birtle, Alison J, Thalmann, George, Graham, John D, Spears, Melissa R, Brock, Susannah, Srinivasan, Rajaguru, Protheroe, Andrew, Sydes, Matthew R, Laing, Robert, Cross, William, Matheson, David, Tsang, David, Parmar, Mahesh K B, Sundar, Santhanam, McKinna, Fiona, Parikh, Omi, Chowdhury, Simon, Robinson, Angus J, De Bono, Johann, Elliott, Tony, Mason, Malcolm D, Parker, Christopher C, Alzouebi, Mymoona, Gibbs, Stephanie, Dearnaley, David P, Millman, Robin, Russell, J Martin, Tolan, Shaun, Chakraborti, Prabir, Cathomas, Richard, Srihari, Narayanan, Clarke, Noel W, Peedell, Clive, James, Nicholas D, Staffurth, John, Gale, Joanna, Hetherington, John, Amos, Claire, Attard, Gerhardt, Hughes, Robert, Jones, Rob J, Ritchie, Alastair W S, McLaren, Duncan B, Wagstaff, John

Publikováno v: James, N D, Sydes, M R, Clarke, N W, Mason, M D, Dearnaley, D P, Spears, M R, Ritchie, A W S, Parker, C C, Russell, J M, Attard, G, de Bono, J, Cross, W, Jones, R J, Thalmann, G, Amos, C, Matheson, D, Millman, R, Alzouebi, M, Beesley, S, Birtle, A J, Brock, S, Cathomas, R, Chakraborti, P, Chowdhury, S, Cook, A, Elliott, T, Gale, J, Gibbs, S, Graham, J D, Hetherington, J, Hughes, R, Laing, R, McKinna, F, McLaren, D B, O'Sullivan, J M, Parikh, O, Peedell, C, Protheroe, A, Robinson, A J, Srihari, N, Srinivasan, R, Staffurth, J, Sundar, S, Tolan, S, Tsang, D, Wagstaff, J, Parmar, M K B & STAMPEDE investigators 2016, ' Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial ', Lancet, vol. 387, no. 10024, pp. 1163–1177 . https://doi.org/10.1016/S0140-6736(15)01037-5
Lancet (London, England), vol. 387, no. 10024, pp. 1163-1177
Lancet, vol. 387, no. 10024, pp. 1163-1177
James, Nicholas D; Sydes, Matthew R; Clarke, Noel W; Mason, Malcolm D; Dearnaley, David P; Spears, Melissa R; Ritchie, Alastair W S; Parker, Christopher C; Russell, J Martin; Attard, Gerhardt; de Bono, Johann; Cross, William; Jones, Rob J; Thalmann, George; Amos, Claire; Matheson, David; Millman, Robin; Alzouebi, Mymoona; Beesley, Sharon; Birtle, Alison J; ... (2016). Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet, 387(10024), pp. 1163-1177. Elsevier 10.1016/S0140-6736(15)01037-5

BACKGROUND: Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with high-risk, locally advanced

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::262e0622007f03a2f7ea0b9d0272734e